BDSI Seeks OK of Oral Anti-Fungal Drug
Posted on: Friday, 2 February 2007, 12:00 CST
U.S. firm BDSI said Friday the Food and Drug Administration has accepted its marketing application for its anti-fungal Bioral Amphotericin.
The company said the treatment for which it is seeking FDA approval is an oral version of its intravenous-administered Amphotericin B (CAMB), which it said is a potent, broadly active antifungicidal agent for treating infections such as esophageal candidiasis, an infection common in HIV patients and in patients getting chemotherapy for cancer.
The therapy also shows promise against other infections like the parasitic disease Leishmaniasis, which affects an estimated 2 million people worldwide, BDSI said.
The IV-based Amphotericin B products currently marketed are effective but limited in their use, due to the need for IV administration, as well as toxicity and cost issues, BDSI added.
CAMB would be the first broadly effective oral antifungicidal agent available in the world, if clinical trials are successful and the product achieves marketing approval, said Mark Sirgo, president and chief executive officer of BDSI. As such, it could have a major impact on the treatment and prophylaxis of fungal infections.
Source: United Press International
Related Articles
- BioDelivery Sciences Initiates Bioral(R) Amphotericin B Clinical Program
- BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
- BDSI Announces FDA Acceptance of Bioral(R) Amphotericin IND
- European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
- FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients
- Nektar Inhaled Anti Infective Given Orphan Designation
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients
- BDSI Names Mark Sirgo As Chief Executive Officer
 |
 |
User Comments (0)
RSS Feeds